These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

141 related articles for article (PubMed ID: 21277015)

  • 1. CRP: star trekking the galaxy of risk markers.
    Després JP
    Lancet; 2011 Feb; 377(9764):441-2. PubMed ID: 21277015
    [No Abstract]   [Full Text] [Related]  

  • 2. C-reactive protein concentration and the vascular benefits of statin therapy: an analysis of 20,536 patients in the Heart Protection Study.
    ; Jonathan Emberson ; Derrick Bennett ; Emma Link ; Sarah Parish ; John Danesh ; Jane Armitage ; Rory Collins
    Lancet; 2011 Feb; 377(9764):469-76. PubMed ID: 21277016
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Lipoproteins and cardiovascular risk.
    Rosch PJ
    Lancet; 2003 Jun; 361(9373):1988; author reply 1989. PubMed ID: 12801766
    [No Abstract]   [Full Text] [Related]  

  • 4. C-reactive protein and cardiovascular risk: more fuel to the fire.
    Boekholdt SM; Kastelein JJ
    Lancet; 2010 Jan; 375(9709):95-6. PubMed ID: 20031200
    [No Abstract]   [Full Text] [Related]  

  • 5. [CRP level as risk marker of cardiovascular disease?].
    Thelle DS; Arnesen E
    Tidsskr Nor Laegeforen; 2010 Mar; 130(5):512-4. PubMed ID: 20224622
    [No Abstract]   [Full Text] [Related]  

  • 6. C-reactive protein levels and outcomes after statin therapy.
    Clearfield M
    Curr Atheroscler Rep; 2006 Jan; 8(1):8-9. PubMed ID: 16455006
    [No Abstract]   [Full Text] [Related]  

  • 7. Importance of intensive lipid lowering in acute coronary syndrome and percutaneous coronary intervention.
    Kumar A; Cannon CP
    J Interv Cardiol; 2007 Dec; 20(6):447-57. PubMed ID: 18042049
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Number needed to treat with rosuvastatin to prevent first cardiovascular events and death among men and women with low low-density lipoprotein cholesterol and elevated high-sensitivity C-reactive protein: justification for the use of statins in prevention: an intervention trial evaluating rosuvastatin (JUPITER).
    Ridker PM; MacFadyen JG; Fonseca FA; Genest J; Gotto AM; Kastelein JJ; Koenig W; Libby P; Lorenzatti AJ; Nordestgaard BG; Shepherd J; Willerson JT; Glynn RJ;
    Circ Cardiovasc Qual Outcomes; 2009 Nov; 2(6):616-23. PubMed ID: 20031900
    [TBL] [Abstract][Full Text] [Related]  

  • 9. C-reactive protein levels and outcomes after statin therapy.
    Ridker PM; Cannon CP; Morrow D; Rifai N; Rose LM; McCabe CH; Pfeffer MA; Braunwald E;
    N Engl J Med; 2005 Jan; 352(1):20-8. PubMed ID: 15635109
    [TBL] [Abstract][Full Text] [Related]  

  • 10. C-reactive protein and cholesterol are equally strong predictors of cardiovascular risk and both are important for quality clinical care.
    Ridker PM; Kastelein JJ; Genest J; Koenig W
    Eur Heart J; 2013 May; 34(17):1258-61. PubMed ID: 23376447
    [No Abstract]   [Full Text] [Related]  

  • 11. [Association of CRP and cardiac effects of statins?].
    Erbel R
    Dtsch Med Wochenschr; 2011 Sep; 136(38):1918. PubMed ID: 21915809
    [No Abstract]   [Full Text] [Related]  

  • 12. High-sensitivity C-reactive protein and cardiovascular disease: a resolute belief or an elusive link?
    Yousuf O; Mohanty BD; Martin SS; Joshi PH; Blaha MJ; Nasir K; Blumenthal RS; Budoff MJ
    J Am Coll Cardiol; 2013 Jul; 62(5):397-408. PubMed ID: 23727085
    [TBL] [Abstract][Full Text] [Related]  

  • 13. [Treatment with hydroxymethylglutaryl coenzyme-A-reductase inhibitors in elderly patients: is it necessary?].
    Alexa ID; Panaghiu L; Ungureanu G
    Rev Med Chir Soc Med Nat Iasi; 2005; 109(4):721-6. PubMed ID: 16610166
    [TBL] [Abstract][Full Text] [Related]  

  • 14. [Effects of aggressive therapy with simvastatin in patients with acute coronary syndrome and initially normal level of LDLP cholesterol on cardiovascular outcomes (LAOKOON). Pilot randomized trial].
    Arutiunov GP; Kartseva TP; Voevodina NIu; Daĭter II; Malanichev RV; Marfunina AA; Nakhaev VI; Rozanov AV; Rylova AK; Stepanova LV
    Ter Arkh; 2005; 77(9):53-60. PubMed ID: 16281491
    [TBL] [Abstract][Full Text] [Related]  

  • 15. In brief: Zetia and Vytorin: the ENHANCE study.
    Med Lett Drugs Ther; 2008 Jan; 50(1278):5. PubMed ID: 18219263
    [No Abstract]   [Full Text] [Related]  

  • 16. Altering the pathophysiology of atherosclerosis: the multidimensional role of statins.
    Clearfield MB
    J Am Osteopath Assoc; 2010 Apr; 110(4 Suppl 4):S2-6. PubMed ID: 20453192
    [TBL] [Abstract][Full Text] [Related]  

  • 17. [Coronary disease prevention: only the inhibition of inflammation is important. Why lower lipids, too?].
    Sudhop T; von Bergmann K
    MMW Fortschr Med; 2003 May; 145(21):19. PubMed ID: 12845862
    [No Abstract]   [Full Text] [Related]  

  • 18. Biomarkers and surrogate endpoints in cardiovascular therapeutics research: under scrutiny following results of the ENHANCE Study.
    Pauriah M; Struthers AD; Lang CC
    Cardiovasc Ther; 2008; 26(2):85-8. PubMed ID: 18485130
    [No Abstract]   [Full Text] [Related]  

  • 19. JUPITER study highlights value of anti-inflammatory action of rosuvastatin.
    Cardiovasc J Afr; 2009; 20(3):211. PubMed ID: 19575096
    [No Abstract]   [Full Text] [Related]  

  • 20. [Comment from the lipidologic viewpoint].
    Riesen WF
    Praxis (Bern 1994); 2009 Feb; 98(3):125-7. PubMed ID: 19180437
    [No Abstract]   [Full Text] [Related]  

    [Next]    [New Search]
    of 8.